Until I met Nurse Williamson who has become HUGE advocate for me while addressing all my concerns
Particulate matter indicates aggregation, a sign of partial denaturation
Sulfate transporters [e.g., SLC13: human Na + -sulfate/carboxylate co-transporter family (Hu et al., 2020)] may be responsible for carrying selenate across the barrier since it is isomorphic to sulfate
Compounding pharmacies formulate their own solutions, and the stability profile varies from pharmacy to pharmacy
How to Prevent It Strengthen diagnostic accuracy every prescription begins with the right diagnosis Use e-prescribing with Clinical Decision Support (CDS) flag mismatched drugs Clinical Pharmacologist and Pharmacist involvement NABH encourages multi-disciplinary medication review Apply tools Beers & STOPP/START criteria in geriatrics Adhere to CDSCO pharmacovigilance report ADRs and near-misses Continuous education & CME update on national and WHO treatment guidelines The Bigger Picture Incorrect drug selection isnt just a clinicians error it reflects systemic gaps in diagnostic reasoning and medication governance

available only through 503A compounding or research supply SNRI drugs covered / venlafaxine (Effexor XR) and duloxetine (Cymbalta) Primary interaction concern / overlapping serotonergic and vasopressive effects DDI severity grading / not classifiable (no human PK/PD interaction studies exist) Serotonin syndrome incidence with SNRI monotherapy / estimated 0.07 per 1,000 patient-years per pharmacovigilance data Venlafaxine CYP pathway / CYP2D6 (major), CYP3A4 (minor) Duloxetine CYP pathway / CYP1A2 (major), CYP2D6 (moderate) BPC-157 CYP interaction profile / unknown in humans